Skip to main content
. 2011 Jul 1;2(7):538–550. doi: 10.18632/oncotarget.302

Table 2.

Effects of Combination of Chemotherapeutic, Hormone Based and Signal Transduction Inhibitors IC50s.1

Cell Line Drug Treatment Change in IC502
MCF-7 Doxorubicin + 5 nM 4HT 7.5 X↓2
MCF-7/ΔAkt-1(CA) Doxorubicin + 5 nM 4HT 10.7 X↓2
MCF-7/ΔAkt-1(CA)DoxR Doxorubicin + 5 nM 4HT 8.9 X↓2
MCF-7 Doxorubicin + 1 nM Rapamycin -2
MCF-7/ΔAkt-1(CA) Doxorubicin + 1 nM Rapamycin 2.5 X↓2
MCF-7/ΔAkt-1(CA)DoxR Doxorubicin + 1 nM Rapamycin 60 X↓2
MCF-7 Etoposide + 1 nM Rapamycin -2
MCF-7/ΔAkt-1(CA) Etoposide + 1 nM Rapamycin 1.3 X↓2
MCF-7/ΔAkt-1(CA)DoxR Etoposide + 1 nM Rapamycin 2.5 X↓2
MCF-7 4HT + 1 nM Rapamycin 5.8 X↓2
MCF-7/ΔAkt-1(CA) 4HT + 1 nM Rapamycin 18.7 X↓2
MCF-7/ΔAkt-1(CA)DoxR 4HT + 1 nM Rapamycin 60 X↓2

1 Determined by MTT analysis as presented in Figures 3, 4 & 5.

2 Comparison with identical cell line treated the same day with just single chemotherapeutic- or hormone based drug, averages of 3 experiments (See Figures 4 and 5 for examples). - = no difference compared to same cell line. X↑ = fold increase in IC50. X↓ = fold decrease in IC50.